News

3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...
BioSpace22h
Lilly’s Antibody Protects Patients From Losing Muscle While Taking Novo’s Wegovy
Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...
Eli Lilly Mounjaro Sees Strong Reception in India, Rising Demand Amid Obesity, Diabetes Rates
Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli ...
Novo Nordisk launches weight-loss drug Wegovy in India to compete with rival Lilly's Mounjaro
By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss ...
Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
Chinese Biotech Showcases Challenger to Eli Lilly’s Obesity Drug
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...
Zacks Investment Research on MSN5d
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.
The Pharma Letter4d
High-dose Wegovy cuts weight 21%, new data shows
At a time when Novo Nordisk has appeared to be slipping behind rival Eli Lilly and its blockbuster Zepbound (tirzepatide) in ...